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Abstract:  Subtilase cytotoxin (SubAB) is the prototype of a new AB5 toxin family 
produced by a subset of Shiga toxigenic Escherichia coli (STEC) strains. Its A subunit is a 
subtilase-like serine protease and cytotoxicity for eukaryotic cells is due to a highly 
specific, single-site cleavage of BiP/GRP78, an essential Hsp70 family chaperone located 
in the endoplasmic reticulum (ER). This cleavage triggers a severe and unresolved ER 
stress response, ultimately triggering apoptosis. The B subunit has specificity for glycans 
terminating in the sialic acid N-glycolylneuraminic acid. Although its actual role in human 
disease pathogenesis is yet to be established, SubAB is lethal for mice and induces 
pathological features overlapping those seen in the haemolytic uraemic syndrome, a life-
threatening complication of STEC infection. The toxin is also proving to be a useful tool 
for probing the role of BiP and ER stress in a variety of cellular functions. 
Keywords:  subtilase cytotoxin; AB5 toxin; BiP/GRP78; endoplasmic reticulum stress; 
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1. Introduction 
AB5 toxins are key virulence factors for several notorious bacterial pathogens, which collectively 
cause massive global morbidity and mortality, particularly amongst children in developing countries. 
There are three well-characterized AB5 toxin families, namely the Shiga toxins (Stx) produced by 
Shiga toxigenic Escherichia coli (STEC) and Shigella dysenteriae, cholera toxin (Ctx) and the closely 
related labile enterotoxins (LT) produced by Vibrio cholerae and enterotoxigenic E. coli, respectively, 
OPEN ACCESSToxins 2010, 2                             
 
 
216
and pertussis toxin (Ptx) produced by Bordetella pertussis. AB5 toxins are characterized by enzymatic 
A subunits capable of disrupting critical host cell functions, non-covalently linked to pentameric B 
subunits that bind to specific glycan receptors on target eukaryotic cells triggering toxin uptake [1]. 
The A subunits of Stx toxins are RNA-N-glycosidases which cleave a specific adenine base in 28S 
rRNA, thereby inhibiting eukaryotic protein synthesis in the same manner as the plant toxin ricin. The 
A subunits of Ctx/LT and Ptx are ADP-ribosylases which modify distinct host G proteins, resulting in 
alteration of intracellular cAMP levels and disregulation of ion transport mechanisms [1]. Subtilase 
cytotoxin (SubAB) is the prototype of a fourth AB5 toxin family, with a mechanism of action that 
differs from that of the other three families [2]. Here we summarise current knowledge regarding the 
molecular and cellular biology, role in disease pathogenesis, and potential cell biological applications 
of this new toxin.  
2. Basic Biological Characterisation 
SubAB was discovered in a strain of STEC belonging to serotype O113:H21 that caused an 
outbreak of haemolytic uraemic syndrome (HUS) in South Australia [3]. HUS is a life-threatening 
systemic complication of STEC infection, characterised by a triad of microangiopathic haemolytic 
anaemia, thrombocytopoenia and renal failure. These features are a direct manifestation of endothelial 
damage believed to be caused by Stx after absorption into the circulation from the gut lumen [4]. 
O113:H21 is a prominent STEC serotype frequently associated with serious human disease, and was 
among the first STEC serotypes to be causally associated with HUS [5]. However, unlike other 
prominent HUS-associated STEC serotypes such as the infamous O157:H7, O113:H21 strains lack the 
locus of enterocyte effacement (LEE), which encodes important accessory virulence traits promoting 
intestinal colonization and gastrointestinal pathology. The clinical presentation was also unusual in this 
particular outbreak, as the affected patients exhibited more marked neurological involvement than in 
previous HUS cases seen at the same hospital. This led us to hypothesise that O113:H21 and perhaps 
some other virulent STEC strains might produce an additional cytotoxin capable of either augmenting 
the effects of Stx or causing pathology in its own right.  
We then used recombinant DNA technology to demonstrate that the O113:H21 STEC genome 
encodes a toxin with a distinct cytopathic effect on Vero cells to that of Stx; it was maximal after three 
days incubation and featured rounding of cells, detachment from the substratum, and loss of viability 
[2]. The novel toxin operon consists of two closely linked genes, designated subA and subB, located on 
the O113:H21 megaplasmid pO113. The subA gene encodes a 347 amino acid protein with similarity 
to members of the Peptidase_S8 (subtilase) family of serine proteases (pfam00082.8). Its closest 
bacterial relative is the BA_2875 gene product of Bacillus anthracis. SubA contains a “catalytic triad” 
comprising conserved Asp, His and Ser domains characteristic of members of the subtilase family [6]. 
It matches consensus sequences for these domains at 11/12, 10/11 and 10/11 positions, respectively, 
including the known critical active site residues Asp52, His89 and Ser272 [2]. The subB gene is 16 
nucleotides downstream of subA and encodes a 141 amino acid protein with significant similarities to 
putative exported proteins from Yersinia pestis  (YPO0337; 56% identity, 79% similarity over   
136 amino acids) and Salmonella Typhi (STY1891; 50% identity, 68% similarity over 117 amino Toxins 2010, 2                             
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acids). STY1891 has significant similarity (30% identity over 101 amino acids) to the S2 subunit of 
Ptx, but there is only 18% identity between SubB and the latter [2].  
Both subA and subB genes are required for expression of cytotoxicity in E. coli, and this can be 
abolished by mutagenesis of any one of the three critical A subunit residues referred to above. Thus, 
serine protease activity is fundamental to the cytotoxic mechanism. The holotoxin is highly toxic for a 
range of cell types and for Vero cells, less than 0.1 pg is sufficient to kill at least 50% of the monolayer 
in a microplate well after 3 days [2]. This is 10–100 times more potent than the specific Vero cell 
cytotoxicities previously reported for both major Stx toxin types [7–11]. However, Morinaga et al. [12] 
have reported an additional vacuolating activity of SubAB, which appeared to be due to SubB alone. 
This occurred at early time points, before the SubA-dependent, protease-mediated cytotoxicity became 
apparent, and required high toxin doses (>1 μg/mL). More recently, Lass et al. [13] described a similar 
phenotype in SubAB-treated HeLa cells, with formation of numerous vacuoles derived from elements 
of the ER, Golgi and probably also the mitochondria, coupled with appearance of lipid droplets in the 
cytoplasm. Notably, however, these changes were dependent on the proteolytic activity of SubA, as 
they were not seen in cells treated with a SubAB derivative with an active site Ser272-Ala mutation 
(SubAA272B).  
3. Intracellular Target and Cytotoxic Mechanism 
The intracellular target of SubA was identified by subjecting toxin-treated Vero cells to proteomic 
analysis. A 28 kDa fragment corresponding to the C-terminus of BiP (GRP78) was detected in cells 
treated with SubAB, but not SubAA272B [14]. BiP is a Hsp70 family chaperone located in the 
endoplasmic reticulum (ER), and the toxin cleaves a di-leucine motif (Leu416–Leu417) in the hinge 
region connecting its N-terminal ATPase and C-terminal protein-binding domains. BiP’s function is to 
bind to exposed hydrophobic regions of nascent secretory proteins in the ER lumen via its C-terminus; 
subsequent release is coupled with ATP hydrolysis and facilitates folding of the proteins into their 
correct conformation. BiP also maintains the permeability barrier of the ER membrane, and targets 
terminally mis-folded proteins via the Sec61 apparatus for degradation by the proteasome. BiP is also 
the master regulator of ER stress signaling responses, and plays a crucial role in triggering the 
unfolded protein response (UPR). It also exhibits anti-apoptotic properties through interference with 
caspase activation [15,16]. Thus, disablement of BiP by SubA-mediated proteolysis would be expected 
to have serious consequences for cell survival. Significantly, transfected Vero cells co-expressing a 
SubA protease-resistant BiP derivative (Leu416Asp) were refractory to SubAB-mediated cytotoxicity, 
directly confirming the central role of BiP cleavage in the lethal mechanism [14]. This mechanism of 
action is unique amongst bacterial toxins. SubA also exhibits exquisite substrate specificity; BiP was 
the only cellular substrate identified in the proteomic screen, and high doses of purified SubA or 
SubAB were incapable of cleaving even the most closely related Hsp70 family chaperones in vitro. 
This is consistent with the crystal structure of SubA which reveals an unusually deep active site cleft, 
relative to other subtilase family proteases [14].  
Although the causal link between cleavage of BiP by SubAB, which can occur within 15 minutes of 
exposure of cells to the toxin, and eventual cell death has been established beyond reasonable doubt, 
our understanding of the intervening molecular events is incomplete. One proven consequence of BiP Toxins 2010, 2                             
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cleavage is a severe ER stress response. This involves a series of changes in cellular activity aimed at 
alleviating the ER stress, so that the cell can restore ER homeostasis and recover [17]. ER stress 
responses include the UPR, which comprises transcriptional up-regulation of ER chaperones 
(including BiP) to boost the folding capacity of the ER, activation of proteasome-dependent   
ER-associated degradation (ERAD) to remove unfolded proteins from the ER lumen, and transient 
inhibition of translation to slow down the traffic of nascent proteins into the ER compartment that 
require folding [17]. In mammals, ER stress responses are triggered by activation of PKR-like ER 
kinase (PERK), inositol-requiring enzyme 1 (IRE1), and activating transcription factor 6 (ATF6). 
These three sentinel proteins span the ER membrane and their luminal domains interact with BiP. 
However, BiP can be competitively displaced when unfolded proteins accumulate in the ER lumen, 
activating the signaling pathways. Activated PERK phosphorylates eIF2α, inhibiting general protein 
synthesis, yet allowing translation of some mRNAs such as ATF4, a transcriptional activator for genes 
that ultimately assist in re-establishing ER homeostasis [18]. After release from BiP, ATF6 traffics to 
the Golgi and is cleaved, releasing a 50-kDa activated form, which translocates to the nucleus. Here it 
binds to the ER stress response element, inducing genes encoding ER chaperones such as BiP, GRP94 
and protein disulphide isomerase, as well as the transcription factors C/EBP homologous protein 
(CHOP) and X-box-binding protein 1 (XBP1). Activation of IRE1 splices XBP1 mRNA such that it is 
translated into XBP1 protein, which then up-regulates genes encoding ER chaperones and the HSP40 
family member P58
IPK. P58
IPK provides a feedback loop by binding and inhibiting PERK, thereby 
relieving the eIF2α-mediated translational block [18]. 
We have shown that in Vero cells, treatment with SubAB activated all three ER stress signaling 
pathways [19]. Active PERK-dependent phosphorylation of eIF2α occurred within 30 min of toxin 
treatment, and correlated with inhibition of translation. Activation of IRE1 was demonstrated by 
splicing of XBP1 mRNA, while ATF6 activation was demonstrated by depletion of the 90-kDa   
un-cleaved form, and appearance of the 50-kDa cleaved form. At least for PERK and IRE1, the 
rapidity with which ER stress signaling responses are triggered by exposure of cells to SubAB is 
consistent with the hypothesis that cleavage by the toxin causes BiP to dissociate from the signaling 
molecules, without the need for accumulation of unfolded proteins in the ER lumen. However, ATF6 
activation in response to SubAB treatment appeared to be markedly slower. Interestingly, BiP has been 
reported to form a stable interaction with ATF6, with dissociation requiring direct triggering mediated 
by an ER stress-responsive sequence in the luminal domain of ATF6 [20]. Thus, accumulation of 
unfolded proteins in SubAB-treated cells may be required before the ATF6 pathway is activated. 
Downstream consequences of BiP cleavage that were detected during the following 24 hour period 
included up-regulation of GRP94, ATF4, EDEM, CHOP, and GADD34. BiP itself was also up-
regulated at the mRNA level, but at the protein level, it continued to be degraded by SubAB in the ER 
lumen, presumably preventing restoration of ER homeostasis [19]. Thus, SubAB treatment induced a 
severe and sustained ER stress response in Vero cells, and at 30 h, there was evidence of apoptosis, as 
judged by DNA fragnentation. Interestingly, SubAB-treated HeLa cells behaved slightly differently, 
with evidence of partial recovery of net synthesis of full length BiP after about 16 h [13]. This might 
be due to a shorter half-life of the toxin in the HeLa cell ER compartment, or to poorer uptake of toxin 
by a sub-population of HeLa cells, perhaps reflecting reduced receptor expression. The latter is 
consistent with the observation that at longer time points, there are two distinct sub-populations of Toxins 2010, 2                             
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SubAB-treated HeLa cells: those that are apoptotic/necrotic, and those that have successfully mounted 
UPR and survived [13]. Notwithstanding these variations, the in vitro findings re activation of the 
PERK, IRE1 and ATF6 pathways are consistent with our observation of CHOP induction in the liver, 
as well as evidence of apoptosis in the kidneys, spleen and liver of SubAB-treated mice [14,21]. 
Morinaga et al. [22] also reported transient inhibition of protein synthesis in SubAB-teated Vero cells 
due to PERK-mediated eIF2α phosphorylation; the toxin also induced cell cycle arrest in G1 phase, 
possibly through down-regulation of cyclin D1 due to a combination of translational inhibition and 
proteasomal degradation. More recently, Matsuura et al. [23] demonstrated SubAB-induced apoptosis 
in Vero cells by DNA fragmentation and annexin V labeling, as well as activation of caspase-3, 
caspase-7 and caspase-8; release of cytochrome c from mitochondria was also demonstrated.  
4. Intracellular Trafficking 
B subunit-mediated binding to cognate glycan receptors on the cell surface is an essential first step 
in intoxication of target cells by AB5 toxins. This triggers internalisation and intracellular trafficking, 
such that the catalytic A subunit has access to its substrate. Fluorescence co-localization with sub-
cellular markers established that like Stx and Ctx, SubAB is trafficked from the cell surface via the 
Golgi to the ER via a retrograde pathway. However, SubAB internalisation and trafficking is 
exclusively clathrin-dependent, whereas Stx or Ctx can also engage the lipid raft transport pathway 
[24]. The route through the Golgi is also distinct, with SubAB exploiting a novel p115/golgin-84-
independent, COG/Rab6/COPI-dependent mechanism, and unlike Stx, retrograde transport is not 
dependent on the endosomal sorting nexins SNX1 and SNX2 [25]. Trafficking of the other AB5 toxins 
also differs from SubAB because their substrates are located in the cytoplasm, while that for SubAB is 
confined to the ER lumen. Thus, the catalytic subunits of the other toxins must also be retro-
translocated across the ER membrane, by subversion of the Sec61 translocon [26,27]. Interestingly, at 
least for StxA, retro-translocation is believed to occur following interaction with BiP and another 
chaperone HEDJ/ERdj3 [27]. SubAB is also known to inhibit ERAD, presumably through reduced 
Sec61-mediated trafficking of substrates [13]. Thus, it is possible that SubAB-mediated BiP cleavage 
might interfere with entry of StxA into the cytosol, and modulate the in vivo consequences of Stx 
intoxication in patients infected with a bacterial strain producing both toxins. 
5. Receptor Specificity 
The B subunits of both Stx and Ctx bind to host cell glycolipids (Gb3 and GM1, respectively) [1], 
whereas the S2 subunit of Ptx binds to sialated glycoproteins [28]. SubB shares about 18% amino acid 
identity with Ptx S2 and binds to N-linked glycans displayed on several glycoproteins on the surface of 
Vero and HeLa cells, including α2β1integrin, which is known to be heavily sialated. Moreover, RNAi 
knock-down of β1integrin in Vero cells abrogated the vacuolating activity of the toxin [29]. Lack of 
involvement of glycolipid receptors is also supported by a recent in vivo study in knock-out mice with 
defects in biosynthesis of a range of glycosphingolipids and gangliosides, none of which were 
protected from SubAB [30]. Byres et al. [31] used glycan array analysis to show that SubB has a high 
degree of specificity for glycans terminating with α2–3-linked N-glycolylneuraminic acid (Neu5Gc) 
with little discrimination for the penultimate moiety. Roughly 20-fold weaker binding was seen with Toxins 2010, 2                             
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otherwise identical glycans that terminated in α2–3-linked N-acetylneuraminic acid (Neu5Ac), which 
differs by one hydroxyl group from Neu5Gc. Binding was reduced over 30-fold if the Neu5Gc linkage 
was changed from α23 to α2–6, and 100-fold if the terminal sialic acid was removed. This high 
specificity for Neu5Gc-terminating glycans is, to the best of our knowledge, unique amongst bacterial 
toxins [31]. 
Structural analysis of SubB confirmed that it forms a homopentameric ring, like CtxB and StxB. In 
spite of modest amino acid sequence identity (18%), there was a high degree of structural similarity 
with the last 100 amino acids of Ptx S2. Neu5Gc bound to a shallow pocket halfway down the sides of 
the SubB pentamer, whereas identical experiments using Neu5Ac failed to show any binding [31]. The 
Ptx S2 sialic acid binding site is also shallow and in the same location [28]. In contrast, the B subunits 
of Stx, Ctx and LT, whose receptors are glycolipids rather than glycoproteins, have deep receptor 
binding pockets located on the base of the pentamer, juxtaposed to the membrane [32–34]. In the 
SubB-Neu5Gc complex, Neu5Gc makes key interactions with the side chains of Asp8, Ser12, Glu36 and 
Tyr78. Neu5Gc differs from Neu5Ac by the addition of a hydroxyl on the methyl group of the N-Acetyl 
moiety, which makes additional crucial interactions with SubB; namely the extra hydroxyl points 
towards and interacts with Tyr78
OH and also hydrogen bonds with the main chain of Met10. These key 
interactions could not occur with Neu5Ac, thus explaining the marked preference for Neu5Gc [31]. 
The biological relevance of the structural analysis was confirmed by mutagenesis of key glycan-
interacting residues in SubB. Mutagenesis of Ser12, Glu36 and Tyr78, respectively, significantly reduced 
cell binding and specific cytotoxicity of the respective holotoxin. Of these, the Ser12 mutation had the 
greatest impact, reducing cytotoxicity by 99.98 per cent. Importantly, mutatgenesis of Tyr78, which 
interacts only with the OH group unique to Neu5Gc, reduced cytotoxicity by 96.9 per cent [31].  
6. Strain Distribution of SubAB 
PCR screening of strain collections indicates that the subAB operon is widely distributed and is 
present in STEC isolates belonging to over 30 O-serogroups emanating from Australia, Japan, Europe, 
North America and South America [2,35–44]. Izumiya et al. [36] have also reported the presence of 
sequence variants in subAB (about 90 per cent identity to the published sequence) amongst the isolates 
from Japan. So far, subAB has been detected almost exclusively in LEE-negative STEC, and there 
appears to be an association between presence of subAB and STEC carrying stx2, or stx1 + stx2, rather 
than stx1 alone [35–44]. However, given that at least in O113:H21, the megaplasmid that carries the 
subAB operon is capable of conjugative transmission [45], there is potential for wider dissemination 
amongst other E. coli pathotypes and possibly other Enterobacteriaceae. Indeed, a very recent study 
has demonstrated the production of SubAB by two non-STEC E. coli strains, belonging to serogroups 
O8 and O78 [44]. These strains were isolated from children with diarrhoea in whom no other enteric 
pathogens were detected, providing the first evidence, albeit circumstantial, for a role for SubAB in 
human diarrhoea. Sequence analysis indicated the subAB operon in these strains was about 90% 
identical to that of the prototype from STEC O113:H21. Moreover, it was encoded on the 
chromosome, rather than on a plasmid [44]. Clearly, mass PCR screening of stool specimens from 
humans or animals, rather than testing specific isolates, will be needed to provide a more complete 
picture of the prevalence and distribution of SubAB-producing bacteria. Toxins 2010, 2                             
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7. Pathological Features and Potential Role in Human Disease 
To date, the in vivo effects of SubAB have only been examined in mice. Gut colonisation with 
recombinant E. coli carrying the subAB operon on a low copy-number plasmid did not cause obvious 
diarrhoea, but nevertheless resulted in dramatic weight loss (approximately 15 per cent) over a 6-day 
period. In contrast, mice colonised with a clone expressing the non-toxic mutant subAA272B operon 
continued to thrive. Interestingly, toxin-affected mice appeared to recover and gained weight after 
about 6 days, and this correlated with sero-conversion against the toxin [2]. In a separate study, 
immunisation with purified SubAA272B also protected mice from weight loss induced by subsequent 
colonisation with E. coli  expressing active SubAB [46]. Interestingly, intraperitoneal injection of 
purified SubAB resulted in microangiopathic haemolytic anaemia, thrombocytopoenia and renal 
impairment in mice. This triad of features defines Stx-induced HUS in humans. There was extensive 
microvascular thrombosis and other histological damage in the brain, kidneys and liver, as well as 
dramatic splenic atrophy. Peripheral blood leukocytes were raised at 24 hours and there was also 
significant neutrophil infiltration in the liver, kidneys and spleen, as well as toxin-induced apoptosis at 
these sites [21]. Doses as low as 200 ng were lethal and survival time after intraperitoneal injection 
was inversely related to toxin dose [2]. SubAB may also have more subtle effects on disease 
pathogenesis, perhaps through immune modulation. SubAB has recently been shown to preferentially 
inhibit antibody secretion of immunoglobulins by activated murine B lymphocytes, leaving cytokine 
secretion relatively unscathed. SubAB preferentially cleaved newly synthesized BiP in these cells, and 
the C-terminal BiP fragment remained tightly bound to nascent immunoglobulin light chains, trapping 
them in the ER compartment [47]. SubAB may also have pro-inflammatory properties. SubAB 
treatment caused transient phosphorylation of Akt and activation of NF-κB in rat renal tubular 
epithelials cells, and this was mediated via the ATF6 branch of the UPR [48]. Activation of NF-κB is 
believed to play an important role in HUS and renal injury. However, at sub-cytotoxic concentrations, 
SubAB has actually been shown to inhibit LPS-mediated NF-κB activation in a murine macrophage 
cell line, and to protect mice from LPS-induced endotoxic lethality and experimental arthritis [49]. 
These findings raise the possibility that SubAB directly contributes to pathology in humans infected 
with strains of STEC that produce both Stx and SubAB. However, direct extrapolation from mice to 
humans is problematic, because of the high specificity of the toxin for receptor glycans terminating in 
Neu5Gc. Humans cannot synthesise this sugar because of a mutation in the Cmah gene, which encodes 
the CMP-N-acetylneuraminic acid hydroxylase that converts CMP-Neu5Ac to CMP-Neu5Gc. This 
mutation occurred about 2 million years ago after evolutionary separation of the Hominin lineage from 
the great apes [50]. This raises the possibility of human genetic hypo-susceptibility to the toxin, as 
uptake would be dependent on lower affinity interactions with Neu5Ac glycans. However, humans 
have been shown to be capable of assimilating Neu5Gc from dietary sources and incorporating it into 
glycoconjugates expressed on epithelial and endothelial surfaces [51]. This would enable expression of 
high-affinity receptors on the cell surface, thereby conferring full susceptibility to SubAB. Indeed, in 
vitro binding of SubAB to human gut epithelium and microvascular endothelium has recently been 
demonstrated [31]. Binding of SubAB to human tissues in vivo would also be facilitated by the absence 
of competing Neu5Gc-containing glycoproteins in human serum or intestinal mucus [31]. Lack of 
protective Neu5Gc-glycoproteins in serum has also been shown to account for the unexpected Toxins 2010, 2                             
 
 
222
susceptibility of Cmah-knock-out mice to injected SubAB [31]. As far as dietary sources of Neu5Gc 
are concerned, it is ironic that the richest sources are red meat and dairy products, and these are also 
the commonest source of STEC contamination. This is a unique paradigm of bacterial pathogenesis, 
whereby humans may directly contribute to disease through dietary choices, simultaneously exposing 
themselves to the risk of STEC infection and sensitising their tissues to SubAB. 
Of course, the hypothesis that SubAB is responsible for disease in humans cannot be tested directly, 
and can only be inferred by epidemiological associations. For example, is there a link between 
production of SubAB and severity of STEC disease in humans or animals? To date, subAB has been 
detected almost exclusively in STEC strains that are LEE-negative, but these strains have been 
considered to be less virulent than LEE-positive strains such as O157:H7. However, microbiological 
diagnostic strategies in those clinical laboratories that test stools for STEC are often tailored 
specifically for detection of O157:H7 strains, rather than STEC per se. This leads to under-detection of 
LEE-negative STEC as etiological agents of disease, skewing the epidemiological data, and limiting 
the number of LEE-negative human STEC isolates available for analysis. Nevertheless, LEE-negative 
strains are quite capable of causing severe disease in humans, and production of SubAB may well 
increase the likelihood of life-threatening complications such as HUS. Argentina has a very high 
incidence of STEC disease and HUS, and comprehensive microbiological investigations have shown 
that many of these cases are caused by LEE-negative STEC strains that also produce SubAB [43]. This 
may provide a sufficient number of cases to examine whether there is an association between SubAB 
production and disease severity. In the meantime, clinicians need to be made aware of the potential for 
a distinct disease spectrum in patients infected with SubAB-producing strains.  
8. Applications of SubAB as a Cell Biological Tool and as a Therapeutic Agent 
The exquisite specificity of SubAB for BiP and its capacity abolish BiP function in vitro and in vivo 
make it a powerful tool for investigation the roles of BiP and ER stress in a range of cellular processes. 
Since BiP is essential for survival of eukaryotic cells, BiP
-/- cell lines and animal models are not 
available, and RNA knock-down approaches are not 100% efficient. In contrast, treatment with SubAB 
results in rapid degradation of virtually all cellular BiP in a wide variety of cell lines, effectively 
mimicking a knock-out phenotype. The toxin has already been used to examine the role of BiP and/or 
ER stress in ERAD in HeLa cells [13], modulation of T-cell activation and inflammatory responses of 
a variety of cell types [52–56] and expression and regulation of gap junction function in mesangial 
cells [57]. SubAB has also been employed to demonstrate the critical role of BiP in assembly and 
egress of cytomegalovirus from infected cells [58,59] and in production and processing of dengue 
virus proteins [60]. Both viruses upregulate BiP during infection, and SubAB treatment significantly 
reduces infectious virus release. Interestingly, defects in chaperone function, particularly those 
affecting ER stress responses, are now strongly implicated in cellular senescence and a range of 
degenerative conditions including cataracts and Parkinson’s and Alzheimer’s diseases [61]. Thus, 
through its capacity to rapidly and specifically abolish BiP function, SubAB may also enable in vitro 
modeling of key events in the pathogenesis of chaperonopathies.  
SubAB may also have utility as a therapeutic agent. As mentioned previously, sub-cytotoxic doses 
prevented LPS-induced NF-κB-mediated endotoxic lethality and experimental arthritis in mice [49]. Toxins 2010, 2                             
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Certain tumours also up-regulate BiP in response to ER stress induced by rapid growth, and this is a 
crucial anti-apoptotic mechanism. BiP up-regulation is linked to metastatic potential and resistance to 
chemotherapy [62].
 Thus, these tumours should be particularly susceptible to SubAB. However, an 
appropriate targeting strategy would be required to prevent damage to normal tissues if holotoxin were 
to be deployed. Alternatively, the A subunit alone could be delivered via a more tumour-specific 
targeting molecule. For example, epidermal growth factor (EGF) could be used to specifically target 
EGF receptor- (EGFR-) positive tumours (these include melanomas, gliomas, breast, prostate, and 
ovarian cancers). An EGF-SubA fusion protein has recently been shown to kill EGFR-positive rat 
glioma and human breast and prostate cancer cells at picomolar concentrations [63]. Cell lines 
expressing moderate to high levels of EGFR, which is associated with invasiveness and metastatic 
potential, were the most susceptible. Moreover, EGF-SubA acted synergistically with drugs such as 
thapsigargin that induce ER stress, enabling effective deployment at concentrations well below the 
cytotoxicity threshold for each component. EGF-SubA has also been shown to be efficacious in vivo, 
significantly inhibiting tumour growth in mouse xenograft models of human breast and prostate   
cancer [63]. 
9. Conclusions 
This review has summarized the substantial body of knowledge of the biological properties of 
SubAB that has been generated in the six or so years since its initial discovery. However, much 
remains to be learnt. For example, whilst we know that SubAB triggers ER stress signalling pathways, 
the precise molecular and cellular events whereby this leads to apoptosis remain to be elucidated. Our 
understanding of its role in disease in both humans and animals is also minimal. The situation is 
complicated by the fact that with the exception of one very recent report [44], SubAB has been 
detected only in strains of E. coli that also produce Stx, raising fascinating questions regarding the 
relative contributions to pathogenesis of these two highly potent AB5 cytotoxins. In the first instance, 
extensive epidemiological investigations are required to determine whether production of SubAB 
correlates with increased risk of severe complications of STEC disease. Secondly, it is important to 
determine whether Stx and SubAB act in synergism, or whether they antagonise one another. Both 
toxins inhibit protein synthesis; Stx acts directly by modification of eukaryotic 28S rRNA [4], while 
SubAB acts indirectly through activation of eIF2α, as described above. Conversely, SubAB-mediated 
BiP cleavage might interfere with retro-translocation of StxA into the cytosol, limiting access to its 
ribosomal substrate. Both toxins also have distinct effects on inflammatory signaling pathways, which 
may play a significant role in pathogenesis of STEC disease. Understanding these events may be very 
important for clinical management of affected patients. 
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